AFP and neoplasm: Adjuvant TACE significantly reduced early recurrence rates, compared to no TACE treatment, for CTC‐positive patients in the following subgroups: single tumor (25.0% vs 48.7%, P = .012), tumor diameter <5 cm (26.7% vs 50.0%, P = .035), absence of vascular invasion (27.5% vs 56.5%, P = .024), complete tumor capsule (29.8% vs 55.0%, P = .012), AFP level ≤400 ng/mL (27.9% vs 47.2%, P = .031), BCLC stage 0‐A (24.1% vs 47.4%, P = .015), and CNLC stage I (24.1% vs 47.4%, P = .015) in TTR at 2 years.